Specialty Chemicals

Givaudan

Kepler Capital Reiterates Buy Rating on Givaudan with a Price Target of CHF 3,600

Givaudan's Same-Store Sales Exceed Expectations in Q1

Givaudan Launches Scentaurus™ PolyDoux Fragrance Precursor

Givaudan to Invest 55 Million Swiss Francs in France for Natural Ingredients Center

Kepler Capital and Barclays Issue Buy Recommendations for Givaudan, UBS Maintains Hold Rating

Givaudan released FY2025 Q4 earnings on January 29 Pre-Market (EST), actual revenue USD 2.277 B (forecast USD 2.215 B), actual EPS USD 0.6514

Givaudan released FY2025 9 Months Earnings on January 29 Pre-Market EST, actual revenue USD 6.869 B, actual EPS USD 2.1698

Givaudan released FY2025 earnings on January 29 Pre-Market EST, actual revenue USD 9.178 B (forecast USD 9.458 B), actual EPS USD 2.8363

Givaudan released FY2025 Q3 earnings on January 29 Pre-Market (EST), actual revenue USD 2.262 B (forecast USD 2.364 B), actual EPS USD 0.6472

Givaudan to Release FY2025 Earnings on January 29, 2026 (EST), Forecast Revenue USD 9.328 B

Counihan Maintains Modest Buy Rating on Givaudan

Pannuti CFA and Jefferies Maintain Givaudan Stock Rating

Pannuti CFA Analyzes Consumer Defensive Stocks and Recommends Givet

Givaudan Building New Liquid Production Facility in Ohio

Givaudan to Release FY2025 Q3 Earnings on October 14, Pre-Market EST; Forecasted Revenue USD 2.363 B

Givaudan Launches New Facility Construction in Guangzhou

Givaudan released FY2025 Q2 earnings on July 21 (EST), actual revenue USD 2.416 B (forecast USD 2.379 B), actual EPS USD 0.7983

Givaudan released FY2025 Semi-Annual earnings on July 21 (EST), actual revenue USD 4.607 B (forecast USD 4.878 B), actual EPS USD 1.5225

Givaudan released FY2025 Q1 earnings on July 21 (EST), actual revenue USD 2.191 B (forecast USD 2.186 B), actual EPS USD 0.7242

Givaudan to Release FY2025 Semi-Annual Earnings on July 22, 2025 (EST), Forecast Revenue USD 4.914 B

Netcapital

Agape ATP

Tradr 2X Long QBTS Daily ETF

Akanda

Defiance Daily Target 2X Long RGTI ETF

PicoCELA

Tradr 2X Long RGTI Daily ETF

Co-Diagnostics

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NewGenIvf

GVDNY

Givaudan SA (GIVN) has received a Buy rating from Kepler Capital, with a price target of CHF3,600.00, while shares closed at CHF2,779.00. Analyst Philip Ngotho is ranked #1821 among 12193 analysts, and the consensus rating is a Moderate Buy with an average target of CHF3,182.78, indicating a 14.53% upside. Jefferies also maintains a Buy rating with a CHF3,300.00 target.

Tip Ranks

Jefferies Financial

Givaudan SA (GIVN) Receives a Buy from Kepler Capital

KRYAY

FTXG

The global herb & spice extracts market is projected to grow from USD 18.5 billion in 2026 to approximately USD 25.5 billion by 2036, at a CAGR of 3.3%. This growth is driven by consumer demand for natural ingredients across food, nutraceutical, pharmaceutical, and personal care sectors. Key players include Givaudan, Kerry Group, McCormick, Sensient Technologies, and Symrise. The market is evolving with a focus on advanced extraction technologies, clean-label formulations, and sustainable sourcing, reflecting a shift towards high-value, application-driven commercialization.

prnewswire

Kerry Group

Mccormick

Sensient Tech

First Trust NASDAQ Food & Beverage

Invesco Food & Beverage ETF

Symrise AG

Symrise

McCormick & Co MD

03:19 ETHerb & Spice Extracts Market Outlook 2036 with Key Contributions from Givaudan, Kerry Group, McCormick & Company, Sensient Technologies, and Symrise

J.P. Morgan analyst Celine Pannuti upgraded Givaudan SA (GIVN) to a Buy with a price target of CHF3,600.00. This follows a similar Buy rating from Jefferies’s Marcus Dunford-Castro. However, Morgan Stanley maintained a Hold rating on the stock. Pannuti is ranked #10793 out of 12125 analysts according to TipRanks.

JPMorgan Chase

Morgan Stanley

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Positive Report for Givaudan SA (GIVN) from J.P. Morgan

Givaudan reported a 2.8% rise in first-quarter sales, exceeding estimates of 1.9%, driven by strong demand in its fragrance and beauty division, which grew 5.9%. Shares rose 5.6%. However, the taste and well-being division saw a 0.4% decline in organic sales, particularly in South Asia and the Middle East. Currency fluctuations negatively impacted overall sales, which fell 5.2% to 1.88 billion Swiss francs. Givaudan plans price increases in 2026 to counter rising costs, indicating a potential shift towards pricing as a growth driver.

Invezz

Givaudan beats sales estimates as fragrance demand lifts shares

Givaudan AG reported a 5.2% drop in Q1 sales, primarily due to weak performance in its Taste & Wellbeing segment. However, like-for-like (LFL) sales grew by 2.8%. The company aims for 4-6% average LFL sales growth and over 12% average free cash flow by 2030. Fragrance & Beauty sales decreased by 0.6% on a reported basis but increased by 5.9% LFL. Taste & Wellbeing sales fell by 10% reported and 0.4% LFL. Regional sales varied, with Asia Pacific up 4.1% LFL, while Europe saw a decline of 0.4%.

rttnews

Givaudan Q1 Sales Drop 5.2%, LFL Sales Up 2.8%; Sees LFL Sales Growth Ahead

NSRGY

NSRGF

J.P. Morgan analyst Celine Pannuti maintained a Hold rating on Givaudan SA (GIVN) with a price target of CHF3,600.00. Pannuti has an average return of -2.1% and a 41.78% success rate. Previously, Deutsche Bank also issued a Hold rating, while Kepler Capital maintained a Buy rating on March 31.

Nestlé

VG Consumer Stap

Nestlé S.A.

SPDR FD Consumer Staples

Givaudan SA (GIVN) Receives a Hold from J.P. Morgan

The global Citrus Powder Market is projected to grow from USD 10.02 billion in 2026 to USD 20.26 billion by 2036, with a CAGR of 7.3%. This growth is driven by increasing demand for natural flavoring, clean-label products, and applications in functional foods. Key drivers include the shift towards natural vitamin C sources, expansion in functional beverages, and rising plant-based food innovation. Major players include Givaudan and Van Drunen Farms, with India identified as the fastest-growing market. The market is characterized by tiered pricing and a moderately consolidated competitive landscape.

MorningStar

Citrus Powder Market to Reach USD 20.26 Billion by 2036, | Functional Foods Drive Demand as Givaudan, Vita-Pakt, and Van Drunen Farms Expand

Givaudan Active Beauty has partnered with Haut.AI to showcase AI-driven ingredient innovations at in-cosmetics Global 2026 in Paris. Attendees will experience immersive GenAI-powered activations, including a virtual try-on of the new active ingredient, PrimalHyal™ NeuroYouth, which targets Neuro Skin Ageing. The collaboration aims to enhance consumer engagement through AI skin analysis and personalized recommendations. Haut.AI will also exhibit its own technologies, including Skin.Chat and Face Analysis 3.0, at the event. Both companies emphasize the importance of AI in advancing beauty ingredient innovation and consumer experience.

02:00 ETGivaudan Active Beauty Showcases AI-Powered Ingredient Innovations with Haut.AI at in-cosmetics Global 2026

Givaudan(GVDNY.US)